MOLOGEN AG
MOLOGEN AG publishes nine month report for 2014: launch of pivotal study for the cancer immunotherapy MGN1703
MOLOGEN AG / Key word(s): 9-month figures MOLOGEN AG publishes nine month report for 2014: launch of pivotal study for the cancer immunotherapy MGN1703 – Start of patient enrolment for IMPALA (phase III) colorectal cancer study – New generation of immunomodulators introduced for the first time – Financial situation remains stable Berlin, 13 November 2014 – The biotechnology company MOLOGEN AG today presented its nine month report for 2014. Considerable progress has been made in the clinical development of the cancer immunotherapy MGN1703. This included the launch of a randomized trial in the area of small cell lung cancer as well as a phase III pivotal study in the field of colorectal cancer. In addition, the company presented EnanDIM, a new generation of immunomodulators, to the scientific community for the first time at the beginning of October 2014. These advancements are reflected in the increased expenses for research and development activities. “We have reached a key milestone in the clinical development of our lead product candidate MGN1703,” comments Dr Matthias Schroff, CEO of MOLOGEN. “In the third quarter, our company has started the treatment of first patients in the IMPALA study, which is our pivotal study for colorectal cancer.” The IMPALA study will include 540 patients from eight European countries. The study is being conducted in cooperation with globally renowned oncology experts as investigators. Patient enrolment for the randomized IMPULSE study, which was launched at the end of the first quarter, continues. The study is investigating the efficacy of MGN1703 in the indication of small cell lung cancer. EnanDIM: a new generation of immunomodulator MGN1601, a therapeutic vaccine against renal cancer, is a further product candidate in clinical development. In the third quarter, data from a completed clinical phase I/II trial (ASET) on MGN1601 was presented at the international ESMO Congress (European Society for Medical Oncology). Research expenses have increased due to the ongoing studies. MOLOGEN continues to have stable finances as a result of a capital increase that was implemented in February. As at the end of third quarter of 2014, MOLOGEN AG had cash and cash equivalents of around 18 million Euros. The nine month report published today confirms our forecast for the year as a whole, as stated in previous quarterly reports. The Executive Board is expecting the net loss for the year to be considerably above the comparable figure for the previous year on account of the increased R&D investments. The complete MOLOGEN report as of September 30, 2014 can be found online at: http://www.mologen.com/de/investoren-presse.html.
The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
13.11.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | info@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
296900 13.11.2014 |